Biogen Idec to Highlight Innovative Pipeline and Commercial Strategy

Biogen Idec

today will be hosting an Analyst Day to provide an update for the investment community on the company's commercial strategy, select late and early-stage clinical development programs, as well as the revitalization of its research organization. The event will be led by George A. Scangos, Ph.D., Chief Executive Officer, Tony Kingsley, Executive Vice President of Global Commercial Operations, and Douglas Williams, Executive Vice President of Research and Development (R&D), along with other members of the company scientific leadership team. Dr. Scangos said, “I feel good about where Biogen Idec is today and our prospects in 2012 and beyond. We have reestablished excellence in our commercial organization. We have a deep understanding of the multiple sclerosis market and believe that we have the right strategy and insights to grow not only our market share but the market overall with the potential launch of multiple new therapies, beginning with our oral MS drug candidate BG-12. We'll be sharing additional context around our Phase 3 clinical studies for our long-lasting blood factors for hemophilia in preparation for those data readouts later this year. We'll also be showcasing several innovative earlier-stage programs, including a therapy focused on repairing the damage done by MS, that reflect our focus on programs with the greatest potential to improve the lives of people with devastating neurodegenerative and immune diseases.”